JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort

被引：0
作者：
Jean-Christophe Ianotto
Aurélie Chauveau
Dominique Mottier
Valérie Ugo
Christian Berthou
Eric Lippert
Aurélien Delluc
机构：
[1] Centre Hospitalier Universitaire (CHRU) Brest,Institut National de la Santé et de la Recherche Médicale (INSERM)
[2] Institut de Cancéro-Hématologie,undefined
[3] EA-3878 G.E.T.B.O. (Groupe d’Etude de la Thrombose en Bretagne Occidentale),undefined
[4] Centre Hospitalier Universitaire (CHRU) Brest,undefined
[5] Laboratoire d’Hématologie,undefined
[6] Institut National de la Santé et de la Recherche Médicale (INSERM) U1078,undefined
[7] Centre Hospitalier Universitaire (CHRU) Brest,undefined
[8] Département de Médecine Interne et Pneumologie,undefined
[9] Centre Hospitalier Universitaire (CHU) Angers,undefined
[10] Laboratoire d’Hématologie,undefined
来源：
Annals of Hematology | 2017年 / 96卷
关键词：
Calreticulin; JAK2 protein tyrosine kinase; Polycythemia vera; Essential thrombocythemia; Deep vein thrombosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cancer incidence in patients with recurrent unprovoked venous thromboembolism (VTE) is much higher than after a first event, but the incidence of myeloproliferative neoplasms (MPN) in this situation is still unknown. We tested for JAK2V617F and calreticulin mutants, 372 DNA samples of patients treated for (VTR). Among these patients, 10 (2.7%) were carrying JAK2V617F mutation and none of them any of the calreticulin (CALR) mutations. Among the 19 patients who had VTE recurrence under vitamin K antagonists, 4 patients (21.0%) were positive for JAK2V617F. Despite the identification of JAK2V617F mutation, only three patients were diagnosed for MPN despite a median follow-up of 4 years. We showed that the screening for JAK2V617F not CALR mutations should be helpful in this indication especially if recurrence happened under VKA therapy.
引用
收藏
页码：383 / 386
页数：3
相关论文
共 58 条
  • [1] Carrier M(2008)Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 149 323-333
  • [2] Le Gal G(2008)Prevalence of the JAK2 V617F mutation is low among unselected patients with a first episode of unprovoked venous thromboembolism J Thromb Haemost 6 203-205
  • [3] Wells PS(2015)Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism Thromb Haemost 115 225-226
  • [4] Fergusson D(1992)Deep-vein thrombosis and the incidence of subsequent symptomatic cancer N Eng J Med 327 112811-112833
  • [5] Ramsay T(2005)A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144-1148
  • [6] Rodger MA(2013)Somatic mutations of calreticulin in myeloproliferative neoplasms N Engl J Med 369 2379-2390
  • [7] Ugo V(2009)JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis Blood 113 5617-5623
  • [8] Le Gal G(2015)Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis J Hepatol 62 72-74
  • [9] Lecucq L(2014)JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate Haematologica 99 1448-1455
  • [10] eMottier D(2014)Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis Haematologica 99 e98-e101
123456